| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Institutes of Pathology,
*
the Department of Clinical Biochemistry,
and the Department of Clinical Genetics,
Aarhus University Hospital, Aarhus, Denmark
We studied the feasibility of using real-time quantitative PCR to determine HER-2 DNA amplification and mRNA expression in microdissected formalin-fixed, paraffin-embedded breast tumors and compared this with standard immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) methods. Study cases (27 carcinomas and 3 ductal breast carcinoma in situ (DCIS) cases) showed varying Her-2 expression as determined by IHC (HercepTest). In carcinomas, there was a good correlation between HER-2 DNA amplification and strong HER-2 protein expression detected by FISH and IHC, respectively. A single DCIS case was amplified in FISH, but not in IHC. Both HER-2 gene amplification and expression could be quantified in microdissected paraffin-embedded tumors using real-time PCR, DNA and RNA being successfully detected in 146 of 150 (97%) and 141 of 150 (94%) samples, respectively. PCR analysis for HER-2 DNA amplification using the LightCycler HER2/neu DNA Quantification kit (Roche Molecular Biochemicals, Mannheim, Germany) correlated fairly well with IHC and FISH. All IHC HER-2 3+ tumors were amplified according to the kit, as was the FISH-amplified DCIS case. DNA-PCR identified five additional tumors as being amplified. Interestingly, all these scored 2+ with the HercepTest, but were negative using FISH. We believe that real-time quantitative PCR analysis of HER-2 DNA amplification following microdissection represents a useful supplementary or perhaps even an alternative technique for establishing HER-2 status in paraffin-embedded tumors.
This article has been cited by other articles:
 |
|
 |
|
  J Bergqvist, J. Ohd, J Smeds, S Klaar, J Isola, H Nordgren, G. Elmberger, H Hellborg, J Bjohle, A-L Borg, et al. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome Ann. Onc., May 1, 2007; 18(5): 845 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stevens, I. Almanaseer, M. Gonzalez, D. Caglar, R. A. Knudson, R. P. Ketterling, D. S. Schrock, T. A. Seemayer, and J. A. Bridge Analysis of HER2 Gene Amplification Using an Automated Fluorescence in Situ Hybridization Signal Enumeration System J. Mol. Diagn., April 1, 2007; 9(2): 144 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Decock How Accurate Is the Antiprimer Quenching-Based Real-Time PCR for Detection of Her2/neu in Clinical Cancer Samples? Clin. Chem., July 1, 2006; 52(7): 1438 - 1439. [Full Text] [PDF]
|
|
|
|
|
|
C. Delfour, P. Roger, C. Bret, M.-L. Berthe, P. Rochaix, N. Kalfa, P. Raynaud, F. Bibeau, T. Maudelonde, and N. Boulle RCL2, a New Fixative, Preserves Morphology and Nucleic Acid Integrity in Paraffin-Embedded Breast Carcinoma and Microdissected Breast Tumor Cells J. Mol. Diagn., May 1, 2006; 8(2): 157 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Buhl, J. Jurlander, F. S. Jorgensen, A. M. Ottesen, J. B. Cowland, L. M. Gjerdrum, B. V. Hansen, and H. Leffers Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia Blood, April 1, 2006; 107(7): 2904 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Hood, M. M. Darfler, T. G. Guiel, B. Furusato, D. A. Lucas, B. R. Ringeisen, I. A. Sesterhenn, T. P. Conrads, T. D. Veenstra, and D. B. Krizman Proteomic Analysis of Formalin-fixed Prostate Cancer Tissue Mol. Cell. Proteomics, November 1, 2005; 4(11): 1741 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jiang, N. P. Caraway, B. Nebiyou Bekele, H.-Z. Zhang, A. Khanna, H. Wang, R. Li, R. L. Fernandez, T. M. Zaidi, D. A. Johnston, et al. Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5417 - 5424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tse, D. Brault, J. Gligorov, M. Antoine, R. Neumann, J.-P. Lotz, and J. Capeau Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients Clin. Chem., July 1, 2005; 51(7): 1093 - 1101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Brandt Microgenomics: gene expression analysis at the tissue-specific and single-cell levels J. Exp. Bot., February 1, 2005; 56(412): 495 - 505. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
